Prevalence and Risk Factors of Hyperuricemia and Gout: A Cross-sectional Survey from 31 Provinces in Mainland China

Overview

Journal J Transl Int Med

Publisher Sciendo

Specialty General Medicine

Date 2022 Aug 12

PMID 35959454

Authors

Jing Song

Chenye Jin

Zhongyan Shan

Weiping Teng

Jing Li

Affiliations

Soon will be listed here.

Abstract

Background And Objetives: Hyperuricemia (HUA) and gout seriously influence patients' quality of life. The current study was performed to investigate the prevalence of HUA and gout and the related risk factors in Chinese adults.

Methods: Data were collected from the National Survey of Thyroid Disorders and Diabetes (the Thyroid Disease, Iodine Status, and Diabetes National Epidemiological survey [TIDE]), a cross-sectional investigation conducted during 2015-2017. Using a random, multistage, and stratified sampling strategy, a representative sample (78,130 participants aged 18 years and above) was selected from the general population in 31 provinces of mainland China. The weighted prevalence rates of HUA and gout were calculated, and the related risk factors were analyzed.

Results: The weighted prevalence rates of HUA and gout in Chinese adults were 17.7% and 3.2%, respectively. The prevalence of HUA in males linearly decreased with age, while the prevalence in females showed the opposite trend (both for trend < 0.01). The prevalence rate of gout exhibited a rising tendency with age in both genders (both for trend < 0.05). The HUA and gout prevalence rates in males were the highest in Han and Tibetan nationalities, respectively. Logistic regression analysis showed that the morbidities of HUA and gout were differentially associated with age, residence location, nationality, smoking, and other complicating metabolic diseases in the two genders.

Conclusions: There are relatively high prevalence rates of gout and HUA in China, which is currently a developing country. Reducing their burden has become an urgent issue for Chinese people.

Citing Articles

Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies.

DI Pierro F, Rabbani F, Tareen M, Nigar R, Khan A, Zerbinati N Front Nutr. 2025; 12:1519459.

PMID: 39990611 PMC: 11844220. DOI: 10.3389/fnut.2025.1519459.

Lacticaseibacillus casei JS-2 from 'Jiangshui' Reduces Uric Acid and Modulates Gut Microbiota in Hyperuricemia.

Wu J, Wang X, Aga L, Tang L, Tan S, Zhang D Foods. 2025; 14(3).

PMID: 39942000 PMC: 11817023. DOI: 10.3390/foods14030407.

A comprehensive analysis of trends in the burden of gout in China and globally from 1990 to 2021.

Xie S, Xiao H, Xu L, Li G, Zhang F, Luo M Sci Rep. 2025; 15(1):3310.

PMID: 39865102 PMC: 11770106. DOI: 10.1038/s41598-025-86090-z.

Wang J, Liu N, Hu M, Zhang M Eur J Med Res. 2025; 30(1):41.

PMID: 39838438 PMC: 11748523. DOI: 10.1186/s40001-025-02272-5.

Inverse relationship of oxidative balance score with hyperuricemia among Chinese adults: a population-based cross-sectional study.

Peng H, Han Y, Huang J, Qiu W, Chang H, Fang J BMC Public Health. 2025; 25(1):234.

PMID: 39833759 PMC: 11744993. DOI: 10.1186/s12889-025-21419-x.

References

Chen-Xu M, Yokose C, Rai S, Pillinger M, Choi H . Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019; 71(6):991-999. PMC: 6536335. DOI: 10.1002/art.40807. View

Johnson R, Titte S, Cade J, Rideout B, Oliver W . Uric acid, evolution and primitive cultures. Semin Nephrol. 2005; 25(1):3-8. DOI: 10.1016/j.semnephrol.2004.09.002. View

Liu H, Zhang X, Wang Y, Liu B . Prevalence of hyperuricemia among Chinese adults: a national cross-sectional survey using multistage, stratified sampling. J Nephrol. 2014; 27(6):653-8. DOI: 10.1007/s40620-014-0082-z. View

Rai S, Avina-Zubieta J, McCormick N, De Vera M, Shojania K, Sayre E . The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum. 2017; 46(4):451-456. PMC: 5315679. DOI: 10.1016/j.semarthrit.2016.08.006. View

Chopra A, Patil J, Billempelly V, Relwani J, Tandle H . Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD Study. J Assoc Physicians India. 2001; 49:240-6. View

Song P, Wang H, Xia W, Chang X, Wang M, An L . Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 2018; 8(1):4314. PMC: 5847518. DOI: 10.1038/s41598-018-22570-9. View

Bardin T, Bouee S, Clerson P, Chales G, Flipo R, Liote F . Prevalence of Gout in the Adult Population of France. Arthritis Care Res (Hoboken). 2015; 68(2):261-6. DOI: 10.1002/acr.22660. View

Anagnostopoulos I, Zinzaras E, Alexiou I, Papathanasiou A, Davas E, Koutroumpas A . The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet Disord. 2010; 11:98. PMC: 2890601. DOI: 10.1186/1471-2474-11-98. View

Zobbe K, Prieto-Alhambra D, Cordtz R, Hojgaard P, Hindrup J, Kristensen L . Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study. Rheumatology (Oxford). 2018; 58(5):836-839. DOI: 10.1093/rheumatology/key390. View

10.

Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T . Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2007; 67(7):960-6. PMC: 2564789. DOI: 10.1136/ard.2007.076232. View

11.

Rockhill B, Newman B, WEINBERG C . Use and misuse of population attributable fractions. Am J Public Health. 1998; 88(1):15-9. PMC: 1508384. DOI: 10.2105/ajph.88.1.15. View

12.

Yu S, Yang H, Guo X, Zhang X, Zhou Y, Ou Q . Prevalence of hyperuricemia and its correlates in rural Northeast Chinese population: from lifestyle risk factors to metabolic comorbidities. Clin Rheumatol. 2015; 35(5):1207-15. DOI: 10.1007/s10067-015-3051-6. View

13.

Chen Y, Zhang N, Sun G, Guo X, Yu S, Yang H . Metabolically healthy obesity also has risk for hyperuricemia among Chinese general population: A cross-sectional study. Obes Res Clin Pract. 2016; 10 Suppl 1:S84-S95. DOI: 10.1016/j.orcp.2016.03.008. View

14.

El-Safty I, Gadallah M, Shouman A, Nessim D . Subclinical nephrotoxicity caused by smoking and occupational silica exposure among Egyptian industrial workers. Arch Med Res. 2003; 34(5):415-21. DOI: 10.1016/S0188-4409(03)00077-8. View

15.

Ting K, Gill T, Keen H, Tucker G, Hill C . Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. Intern Med J. 2016; 46(5):566-73. DOI: 10.1111/imj.13006. View

16.

Gibson T . Hypertension, its treatment, hyperuricaemia and gout. Curr Opin Rheumatol. 2013; 25(2):217-22. DOI: 10.1097/BOR.0b013e32835cedd4. View

17.

Li Y, Teng D, Shi X, Qin G, Qin Y, Quan H . Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ. 2020; 369:m997. PMC: 7186854. DOI: 10.1136/bmj.m997. View

18.

Sattui S, Singh J, Gaffo A . Comorbidities in patients with crystal diseases and hyperuricemia. Rheum Dis Clin North Am. 2014; 40(2):251-78. PMC: 4159668. DOI: 10.1016/j.rdc.2014.01.005. View

19.

Baggio B, Budakovic A, Dalla Vestra M, Saller A, Bruseghin M, Fioretto P . Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J Am Soc Nephrol. 2002; 13(11):2730-6. DOI: 10.1097/01.asn.0000032422.81130.68. View

20.

Puig J, Mateos F, Miranda M, Torres R, De Miguel E, Perez de Ayala C . Purine metabolism in women with primary gout. Am J Med. 1994; 97(4):332-8. DOI: 10.1016/0002-9343(94)90299-2. View